MCAC To Weigh Emerging Treatments For Age-Related Macular Degeneration
This article was originally published in The Gray Sheet
Executive Summary
CMS' Medicare Coverage Advisory Committee will convene Nov. 29 in Baltimore to evaluate the evidence for age-related macular degeneration (AMD) treatments
You may also be interested in...
AHRQ on gauging macular degeneration
Agency for Healthcare Research & Quality posts final 1technology assessment on the scientific validity of patient-reported outcomes for age-related macular degeneration, identifying vision-specific questionnaires such as NEI-VFQ and VF-14 as the most appropriate quality-of-life instruments that still correspond "moderately" with traditional visual performance measures. CMS' Medicare Coverage Advisory Committee has considered such issues when weighing available evidence supporting AMD treatments (2"The Gray Sheet" Nov. 28, 2005, p. 7)...
AHRQ on gauging macular degeneration
Agency for Healthcare Research & Quality posts final 1technology assessment on the scientific validity of patient-reported outcomes for age-related macular degeneration, identifying vision-specific questionnaires such as NEI-VFQ and VF-14 as the most appropriate quality-of-life instruments that still correspond "moderately" with traditional visual performance measures. CMS' Medicare Coverage Advisory Committee has considered such issues when weighing available evidence supporting AMD treatments (2"The Gray Sheet" Nov. 28, 2005, p. 7)...
MCAC Advises AMD Manufacturers To Conduct Randomized, Controlled Trials
Manufacturers developing treatments for age-related macular degeneration (AMD) should conduct randomized, controlled trials, CMS' Medicare Coverage Advisory Committee recommended at a Nov. 29 meeting in Baltimore